Limone P, Calvelli P, Altare F, Ajmone-Catt P, Lima T, Molinatti G M
Department of Internal Medicine, Regina Margherita Hospital, Torino, Italy.
J Endocrinol Invest. 1997 Apr;20(4):207-10. doi: 10.1007/BF03346904.
Gonadotropin secretion is inhibited by the endogenous opioids and stimulated by their antagonist naloxone. LH secretion is stimulated by alpha-MSH, a tridecapeptide derived from the post-translational processing of POMC. The possibility that alpha-MSH interacts with the opioids, as suggested by the experimental evidence, was investigated in 7 normal males aged 24-29 through the performance of seven tests: naloxone (0.8 mg i.v. bolus, followed by infusion of 1.6 mg/h for 120'); alpha-MSH (2.5 mg i.v. bolus); naloxone + alpha-MSH (2.5 mg i.v. 15' after commencement of the naloxone infusion); naloxone + GnRH (100 micrograms i.v. 15' after commencement of the naloxone infusion); alpha-MSH + GnRH (respectively 2.5 mg and 100 micrograms at time 0), GnRH alone (100 micrograms at time 0), placebo (150 nmol/l NaCl solution). The LH AUCs during both naloxone (30.3 +/- 2.7 mIU/ml.min-1) and alpha-MSH test (32.9 +/- 4.6 mIU/ml.min-1) were significantly greater (p < 0.005) than that observed during placebo (16.9 +/- 3.6 mIU/ml.min-1). The LH AUC during alpha-MSH + naloxone (37.6 +/- 2.6 mIU/ml.min-1) was not significantly different from that recorded during their separate administration. GnRH injected alone, during the naloxone infusion and with alpha-MSH produced similar increases in LH, that were significantly higher than that observed during the other tests (AUCs: GnRH 89.4 +/- 10.6, GnRH + naloxone 100.5 +/- 9.1, GnRH + alpha-MSH 94.6 +/- 7.9 mIU/ml.min-1, p < 0.001). Significant increase in FSH (p < 0.001) was only observed during GnRH, GnRH + naloxone and GnRH + aMSH tests (AUCs: placebo 13.3 +/- 1.7; naloxone 14.7 +/- 2.5; alpha-MSH 15.5 +/- 2.3; alpha-MSH + naloxone 16.9 +/- 1.9; GnRH 19.1 +/- 1.1; GnRH + alpha-MSH 20.7 +/- 1.3; GnRH + naloxone 21.2 +/- 1.8 mIU/ml.min-1). These results are in line with the possibility of an interaction between alpha-MSH and the opioids in the regulation of gonadotropin secretion, perhaps with opposing effects on a final common pathway.
促性腺激素的分泌受内源性阿片类物质抑制,而受其拮抗剂纳洛酮刺激。促黄体生成素(LH)的分泌受α-促黑素细胞激素(α-MSH)刺激,α-MSH是一种由阿片-促黑素细胞皮质素原(POMC)翻译后加工产生的十三肽。根据实验证据所提示的α-MSH与阿片类物质相互作用的可能性,对7名年龄在24至29岁的正常男性进行了七项试验加以研究:纳洛酮(静脉推注0.8mg,随后以1.6mg/h的速度输注120分钟);α-MSH(静脉推注2.5mg);纳洛酮+α-MSH(在纳洛酮输注开始15分钟后静脉注射2.5mg);纳洛酮+促性腺激素释放激素(GnRH,在纳洛酮输注开始15分钟后静脉注射100μg);α-MSH+GnRH(分别在0时刻注射2.5mg和100μg),单独注射GnRH(在0时刻注射100μg),安慰剂(150nmol/L氯化钠溶液)。在纳洛酮试验(30.3±2.7mIU/ml·min⁻¹)和α-MSH试验(32.9±4.6mIU/ml·min⁻¹)期间,LH的曲线下面积(AUC)均显著大于安慰剂试验期间观察到的数值(16.9±3.6mIU/ml·min⁻¹,p<0.005)。α-MSH+纳洛酮试验期间的LH AUC(37.6±2.6mIU/ml·min⁻¹)与单独给药时记录的数值无显著差异。单独注射GnRH、在纳洛酮输注期间注射GnRH以及与α-MSH联合注射GnRH均使LH产生类似的升高,且显著高于其他试验所观察到的数值(AUC:GnRH为89.4±10.6、GnRH+纳洛酮为100.5±9.1、GnRH+α-MSH为94.6±7.9mIU/ml·min⁻¹,p<0.001)。仅在GnRH、GnRH+纳洛酮和GnRH+α-MSH试验期间观察到促卵泡生成素(FSH)有显著升高(p<0.001)(AUC:安慰剂为13.3±1.7;纳洛酮为14.7±2.5;α-MSH为15.5±2.3;α-MSH+纳洛酮为16.9±1.9;GnRH为19.1±1.1;GnRH+α-MSH为20.7±1.3;GnRH+纳洛酮为21.2±1.8mIU/ml·min⁻¹)。这些结果符合α-MSH与阿片类物质在调节促性腺激素分泌过程中相互作用的可能性,可能对最终的共同途径产生相反的影响。